TW202330015A - 作為治療劑之肽微管蛋白抑制劑之肽結合物 - Google Patents

作為治療劑之肽微管蛋白抑制劑之肽結合物 Download PDF

Info

Publication number
TW202330015A
TW202330015A TW111143837A TW111143837A TW202330015A TW 202330015 A TW202330015 A TW 202330015A TW 111143837 A TW111143837 A TW 111143837A TW 111143837 A TW111143837 A TW 111143837A TW 202330015 A TW202330015 A TW 202330015A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
group
Prior art date
Application number
TW111143837A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特 約翰 馬古尼
喬安娜 瑪麗 琴蓋伊
Original Assignee
美商斯布雷克薩四號公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商斯布雷克薩四號公司 filed Critical 美商斯布雷克薩四號公司
Publication of TW202330015A publication Critical patent/TW202330015A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW111143837A 2021-11-17 2022-11-16 作為治療劑之肽微管蛋白抑制劑之肽結合物 TW202330015A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163280409P 2021-11-17 2021-11-17
US63/280,409 2021-11-17

Publications (1)

Publication Number Publication Date
TW202330015A true TW202330015A (zh) 2023-08-01

Family

ID=84799580

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111143837A TW202330015A (zh) 2021-11-17 2022-11-16 作為治療劑之肽微管蛋白抑制劑之肽結合物

Country Status (14)

Country Link
US (1) US20230416331A1 (enExample)
EP (1) EP4433095A1 (enExample)
JP (1) JP2024542212A (enExample)
KR (1) KR20240130157A (enExample)
CN (1) CN118574642A (enExample)
AU (1) AU2022390891A1 (enExample)
CA (1) CA3243300A1 (enExample)
CL (1) CL2024001486A1 (enExample)
CO (1) CO2024007413A2 (enExample)
IL (1) IL312884A (enExample)
MX (1) MX2024005938A (enExample)
PE (1) PE20242180A1 (enExample)
TW (1) TW202330015A (enExample)
WO (1) WO2023091957A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220052918A (ko) 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2399267T3 (es) * 2005-01-18 2013-03-27 The Board Of Governors For Higher Education State Of Rhode Island And Providence Plantations Suministro selectivo de moléculas al interior de las células o marcación de células en zonas enfermas de tejidos usando un péptido transmembrana sensible a su entorno
JP6262768B2 (ja) * 2013-01-03 2018-01-17 セルトリオン， インク． 抗体−リンカー−薬物結合体、その製造方法およびそれを含む抗癌剤組成物
WO2018023098A1 (en) * 2016-07-29 2018-02-01 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
KR20220052918A (ko) * 2019-07-10 2022-04-28 싸이브렉사 2, 인크. 치료제로서의 사이토톡신의 펩티드 접합체
PH12022550037A1 (en) * 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics

Also Published As

Publication number Publication date
CN118574642A (zh) 2024-08-30
EP4433095A1 (en) 2024-09-25
KR20240130157A (ko) 2024-08-28
CL2024001486A1 (es) 2024-11-29
AU2022390891A1 (en) 2024-06-06
PE20242180A1 (es) 2024-11-07
US20230416331A1 (en) 2023-12-28
IL312884A (en) 2024-07-01
CA3243300A1 (en) 2023-05-25
CO2024007413A2 (es) 2024-11-18
WO2023091957A1 (en) 2023-05-25
MX2024005938A (es) 2024-08-14
JP2024542212A (ja) 2024-11-13

Similar Documents

Publication Publication Date Title
JP7673041B2 (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
TWI820077B (zh) 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法
CN112625028B (zh) 用于抑制shp2活性的化合物和组合物
JP2022541749A5 (enExample)
JP7675060B2 (ja) 治療薬としての微小管標的化剤のペプチドコンジュゲート
US20230416331A1 (en) Peptide conjugates of peptidic tubulin inhibitors as therapeutics
WO2023207447A1 (zh) 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
CN118475579A (zh) 作为tead抑制剂的异双功能分子
TWI918605B (zh) 作為治療劑之細胞毒素之肽結合物
EA051761B1 (ru) Пептидные конъюгаты агентов, нацеленных на микротрубочки, в качестве терапевтических средств
WO2022155172A1 (en) Peptide conjugates of therapeutics
EA051826B1 (ru) Пептидные конъюгаты цитотоксинов в качестве терапевтических средств
WO2025151728A1 (en) Ligand directed degrader of irak4